TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15006575

Group type: EXPERIMENTAL
Intervention: Subtotal stomach
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Slender gastric tube
Number of subjects: 44
Study: 11812474

Group type: EXPERIMENTAL
Intervention: Orthofix distally based distal targeting device
Number of subjects: 58

Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 58
Study: 9164362

Group type: EXPERIMENTAL
Intervention: Ipratropium nasal spray (42 micrograms per nostril, administered twice daily for 4 weeks)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo nasal spray (administered twice daily for 4 weeks)
Number of subjects: 202
Study: 7956412

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mechanical ventilation in the prone position
Number of subjects: 12

Group type: COMPARATOR
Intervention: Returning the patient to the supine position
Number of subjects: 12
Study: 3652627

Group type: EXPERIMENTAL
Intervention: Deferoxamine therapy (1 to 6 g intravenously once a week for a mean duration of 7.6 +/- 3.3 months)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Deferoxamine therapy
Number of subjects: 16
Study: 28727673

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 65
Study: 26876735

Group type: EXPERIMENTAL
Intervention: TFA files in continuous rotation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mtwo files in continuous rotation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TFA files in adaptive motion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mtwo files in adaptive motion
Number of subjects: 32
Study: 26286351

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Individual Addiction Counseling (IAC)
Number of subjects: 121
Study: 23583219

Group type: EXPERIMENTAL
Intervention: Digoxin antibody fragment (DIF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20229023

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte (CHO-E) solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-carbohydrate (CHO) placebo
Number of subjects: 15
Study: 16778821

Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conjunctival autograft
Number of subjects: 68
Study: 15661816

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with NOS inhibition (10 mm l-NAME)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with COX inhibition (10 mm ketorolac)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion (137.5 mum) with NOS and COX inhibition
Number of subjects: 22
Study: 11932074

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (20 sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sham-acupuncture (20 sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control condition (physiotherapy)
Number of subjects: 131
Study: 11081007

Group type: EXPERIMENTAL
Intervention: Intervention by an arthritis patient educator
Number of subjects: 108
Study: 7864705

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 1.2 g over 20 minutes after albuterol treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 72
Study: 1771089

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 0
Study: 6185343

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of methotrexate (MTX) 500 mg over 10 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intra-arterial infusion of bleomycin (BLM) 95 mg over 13 days
Number of subjects: 85
Study: 31847208

Group type: EXPERIMENTAL
Intervention: Obese girls and women (defined by BMI)
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Participants with ≥30% body fat percentage (BF%)
Number of subjects: 3623
Study: 30613078

Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound (LIUS) and traditional exercise therapy (TET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) and traditional exercise therapy (TET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional exercise therapy (TET)
Number of subjects: 60
Study: 28779736

Group type: EXPERIMENTAL
Intervention: 4% dietary lipid
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 6% dietary lipid
Number of subjects: 225

Group type: COMPARATOR
Intervention: 0%, 8%, and 12% dietary lipid
Number of subjects: 225
Study: 25074351

Group type: EXPERIMENTAL
Intervention: ibandronate 150 mg/month
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: alendronate 70 mg/week
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: risedronate 35 mg/week
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: oral bisphosphonates (all three types)
Number of subjects: 172
Study: 22935241

Group type: COMPARATOR
Intervention: Standard dissemination (SD) of a guideline package
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SD plus a web-based resource championed by an opinion leader
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SD plus plan-do-study-act (PDSA)
Number of subjects: 19
Study: 19885413

Group type: EXPERIMENTAL
Intervention: Test implants (thin mucosa, group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Test implants (thick mucosa, group B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control implants
Number of subjects: 19
Study: 17163245

Group type: EXPERIMENTAL
Intervention: EE 20microg/drsp 3mg
Number of subjects: 516
Study: 14633055

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Big-Five personality characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agreeableness and Openness
Number of subjects: 0
Study: 10723632

Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg/20 ml
Number of subjects: 14

Group type: COMPARATOR
Intervention: Matched placebo infusions
Number of subjects: 14
Study: 8704691

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue
Number of subjects: 42

Group type: COMPARATOR
Intervention: PBPC instead of marrow
Number of subjects: 42
Study: 1735888

Group type: EXPERIMENTAL
Intervention: Lower extremity arterial duplex mapping
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clinical disease category
Number of subjects: 150
Study: 6361558

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (3 mg/kg initial dose)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31280133

Group type: EXPERIMENTAL
Intervention: Collaborating toward a joint concrete goal of earning resources that could subsequently be shared
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborating toward a joint concrete goal without earning resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Playing a social game without earning resources
Number of subjects: 0
Study: 29659585

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Upper-limb RIPC
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study: 26817441

Group type: EXPERIMENTAL
Intervention: Modified nurse-delivered transitional home visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25029202

Group type: EXPERIMENTAL
Intervention: Calcitriol (2 μg intravenously)
Number of subjects: 67
Study: 23071551

Group type: EXPERIMENTAL
Intervention: Pooled video condition
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Webpage condition
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1631
Study: 20385996

Group type: EXPERIMENTAL
Intervention: Short-course intensive polychemotherapy (in blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy.
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation (SCT) for high-risk groups A plus poor prognosis group (PPG).
Number of subjects: 525

Group type: COMPARATOR
Intervention: Historical controls (not explicitly defined in the abstract).
Number of subjects: 525
Study: 17288680

Group type: EXPERIMENTAL
Intervention: Aspirin 30-325 mg daily
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2739
Study: 16235795

Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned caesarean section
Number of subjects: 0
Study: 11925374

Group type: EXPERIMENTAL
Intervention: Diaphragm with spermicide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaphragm without spermicide
Number of subjects: 0
Study: 10197295

Group type: EXPERIMENTAL
Intervention: Caffeine clearance in pediatric patients with liver diseases (LD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Caffeine clearance in healthy children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urinary molar ratio of [AFMU + 1U + 1X]/17U in pediatric patients with liver diseases (LD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Urinary molar ratio of [AFMU + 1U + 1X]/17U in healthy children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urinary ratios of AFMU/1X and 1U/1X in pediatric patients with liver diseases (LD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Urinary ratios of AFMU/1X and 1U/1X in healthy children
Number of subjects: 18
Study: 7551881

Group type: EXPERIMENTAL
Intervention: Desmopressin 20, 40, and 60 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desmopressin 60 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2273193

Group type: EXPERIMENTAL
Intervention: 0.6 mg riboflavin daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.2 mg riboflavin daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.7 mg riboflavin (one-a-day supplement)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 428372

Group type: EXPERIMENTAL
Intervention: Cycling supine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cycling sitting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alternate arm cranking standing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Walking on a treadmill
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stepping on a bench
Number of subjects: 30
Study: 31618905

Group type: EXPERIMENTAL
Intervention: BB536
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of BB536 and AHCC®
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AHCC®
Number of subjects: 40
Study: 28207507

Group type: EXPERIMENTAL
Intervention: IFN + SOF + RBV
Number of subjects: 533

Group type: COMPARATOR
Intervention: SOF + RBV
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Both regimens (IFN + SOF + RBV and SOF + RBV)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: IFN-based regimens
Number of subjects: 533

Group type: COMPARATOR
Intervention: RBV
Number of subjects: 533
Study: 26270255

Group type: EXPERIMENTAL
Intervention: J-CPAP (variable flow)
Number of subjects: 170

Group type: COMPARATOR
Intervention: B-CPAP (continuous flow)
Number of subjects: 170
Study: 23337559

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 50
Study: 21888870

Group type: EXPERIMENTAL
Intervention: Zednad® Tablet (500 mg cefuroxime/tablet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zinnat® Tablet (500 mg cefuroxime/tablet)
Number of subjects: 24
Study: 19055515

Group type: EXPERIMENTAL
Intervention: High dose aspirin
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Both aspirin combined groups
Number of subjects: 2338

Group type: EXPERIMENTAL
Intervention: Aspirin groups (without considering dose)
Number of subjects: 2338
Study: 16738974

Group type: EXPERIMENTAL
Intervention: Ondansetron and dexamethason
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Antiemetic drugs (groups 1 to 6)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no antiemetic)
Number of subjects: 210
Study: 13679279

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10618572

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the atrioventricular junction
Number of subjects: 156
Study: 8604765

Group type: EXPERIMENTAL
Intervention: Managed care joiners
Number of subjects: 814

Group type: COMPARATOR
Intervention: Non-joiners
Number of subjects: 814

Group type: COMPARATOR
Intervention: Indemnity plan members
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 814
Study: 1550911

Group type: EXPERIMENTAL
Intervention: Intravenous levoprotiline (15 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peroral levoprotiline (75 mg)
Number of subjects: 12
Study: 3933019

Group type: EXPERIMENTAL
Intervention: cream containing l‐cysteine, glycine and dl‐threonine
Number of subjects: 22

Group type: COMPARATOR
Intervention: cream base alone (placebo)
Number of subjects: 22
Study: 30967424

Group type: EXPERIMENTAL
Intervention: Low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ATG and pegylated granulocyte colony-stimulating factor (GCSF)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ATG alone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 29499873

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Self-monitoring vs Telemonitoring
Number of subjects: 1182
Study: 27556735

Group type: EXPERIMENTAL
Intervention: Modeling counts of golden eagles using distance sampling and visual mark-recapture procedures; no specific dosage or duration mentioned as this is observational modeling.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model predictions of habitat use based on survey data from 2006-2010; no specific dosage or duration mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Map predicting intensity of use by golden eagles during late summer across a ∼2 million‐km2 study area; no specific dosage or duration mentioned.
Number of subjects: 0
Study: 24958044

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pleural drainage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (AVSD subset)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pleural drainage (AVSD subset)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (TOF subset)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pleural drainage (TOF subset)
Number of subjects: 24
Study: 21778107

Group type: EXPERIMENTAL
Intervention: Familiar face images
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Own face images
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unfamiliar face images
Number of subjects: 9
Study: 20674654

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (ISWT)
Number of subjects: 30
Study: 17344605

Group type: EXPERIMENTAL
Intervention: Computerized pelvis traction and ultrashort wave
Number of subjects: 84

Group type: COMPARATOR
Intervention: Computerized pelvis traction only
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Computerized pelvis traction, ultrashort wave, and traditional Chinese medicine iontophoresis
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group B (Computerized pelvis traction only)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group A (Computerized pelvis traction and ultrashort wave)
Number of subjects: 84
Study: 15695300

Group type: EXPERIMENTAL
Intervention: Once-weekly oral alendronate (1-2 mg/kg body weight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11876712

Group type: EXPERIMENTAL
Intervention: Tetracycline-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, tetracycline 500 mg four times daily for 7 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Clarithromycin-containing therapy (omeprazole 20 mg twice daily, bismuth 120 mg four times daily, metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 95
Study: 12577331

Group type: EXPERIMENTAL
Intervention: Composite Salviae Injection (CSI) 0.5 ml/kg by intravenous dripping
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline in equal volume (Control)
Number of subjects: 18
Study: 9756307

Group type: EXPERIMENTAL
Intervention: Continuous combined (cc) 2 mg oestradiol valerate and 0.7 mg norethisterone acetate HRT daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both types of HRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Higher post-HRT uterine PP14 concentration
Number of subjects: 30
Study: 10151073

Group type: EXPERIMENTAL
Intervention: Rhinopront syrup (15 g)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Triaminic (commercial standard decongestant)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rhinopront syrup (1 g per year of age)
Number of subjects: 36
Study: 3048053

Group type: EXPERIMENTAL
Intervention: Clonidine (75-300 micrograms daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20
Study: 30246187

Group type: EXPERIMENTAL
Intervention: Supracrestal implants (SC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bone level implants (BL)
Number of subjects: 10
Study: 28441175

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 214
Study: 25933099

Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 150 mg/day
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 200 mg/day
Number of subjects: 492

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 492
Study: 23523362

Group type: EXPERIMENTAL
Intervention: Interdisciplinary cancer support team (CST) intervention consisting of individualized care coordination, symptom management, education, psychosocial and spiritual supports, and advance care planning over 15 months
Number of subjects: 610

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 610
Study: 21551012

Group type: EXPERIMENTAL
Intervention: Experimental warm-up (15 min cycling from 60% to 70% of maximal heart rate, followed by 1 sprint)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional warm-up (20 min cycling from 60% to 95% of maximal heart rate, followed by 4 sprints)
Number of subjects: 2
Study: 19058484

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (two drops in growing concentrations of 500, 1,000, 2,000, 10,000, and 20,000 biological units)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 138
Study: 17154743

Group type: EXPERIMENTAL
Intervention: 10-week group cognitive-behavioral stress management intervention
Number of subjects: 199
Study: 12704348

Group type: EXPERIMENTAL
Intervention: Anti-IL-5 (mepolizumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10913779

Group type: EXPERIMENTAL
Intervention: Topical application of NSAIDs (diclofenac sodium salt, fenoprofen calcium salt, ibuprofen, ketoprofen, nabumetone, sulindac)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of antimicrobial drugs (acyclovir, ampicillin, atovaquone, dapsone, enoxacin, ethambutol, lomefloxacin HCl, ofloxacin, pentamidine isethionate, pyrimethamine, sulfamethoxazole, tetracycline HCl, trimethoprim)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of drugs
Number of subjects: 0
Study: 8807660

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Caffeine 200 mg orally
Number of subjects: 8
Study: 1564678

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (o.c.)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 31999489

Group type: EXPERIMENTAL
Intervention: RT+LP‐L (1.7 mg/kg, low dosage of LP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RT+LP‐M (5.2 mg/kg, middle dosage of LP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RT+LP‐H (10.4 mg/kg, high dosage of LP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: LP during RT (observation group)
Number of subjects: 5

Group type: COMPARATOR
Intervention: RT only (control group)
Number of subjects: 5
Study: 29669604

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg monotherapy)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 336
Study: 28363814

Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration conducted in segmented stages
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: recipe card plus video demonstration whereby participants freely accessed video demonstrations as and when needed
Number of subjects: 141
Study: 25716126

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhalational anesthetic-based balanced general anesthesia
Number of subjects: 30
Study: 23788750

Group type: EXPERIMENTAL
Intervention: Lonaprisan 25 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lonaprisan 100 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lonaprisan (both dosages)
Number of subjects: 68
Study: 20598968

Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 279

Group type: COMPARATOR
Intervention: Open mitral valve surgery (control)
Number of subjects: 279